EYEG News and Press, Eyegate Pharmaceuticals Inc. From 01/11/21

Mesoblaston (MESO) +68% after announcing additional results from the DREAM-HF Phase 3 trial.TransEnterix (TRXC) +64%.LM Funding America (LMFA) +49%.Aileron Therapeutics (ALRN) +35%.Bionano Genomics (BNGO) +24% after announcing first publication from the COVID-19 host genome structur...

EyeGate Pharmaceuticals ([[EYEG]] +5.9%) has entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of ~$8M.EyeGate will issue to Armistice an aggregate of 1,531,101 shares of the its common ...

WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the e...

Gainers: Anterix (ATEX) +67%.NantKwest (NK) +55%.500.com Limited (WBAI) +51%.Editas Medicine (EDIT) +47%.EyeGate Pharmaceuticals (EYEG) +45%.Organovo Holdings (ONVO) +36%.Nuverra Environmental Solutions (NES) +33%.RealPage (RP) +29%.Agios Pharmaceuticals (AGIO) +29%.CuriosityStream (CURI...

Gainers: EyeGate Pharmaceuticals (EYEG) +78%, Editas Medicine (EDIT) +42%, NantKwest (NK) +30%, Liminal BioSciences (LMNL) +29%, Agios Pharmaceuticals (AGIO) +24%.Losers: Scopus BioPharma (SCPS) -17%, uniQure (QURE) -16%, C...

EyeGate Pharmaceuticals (EYEG) +87% as it acquires Panoptes Pharma.NantKwest (NK) +32% as its partner, ImmunityBio, achieves primary endpoint in bladder cancer study.RealPage (RP) +31% as Thoma Bravo has agreed to buy the company for $9.6B.China Customer Relations Centers (CCRC...

EyeGate Pharmaceuticals (EYEG) is acquiring Belgium-based Panoptes Pharma for $4M in cash and stock to broaden its pipeline targeting eye disorders. The shares of EyeGate have surged +67.8% in pre-market trading.As part of the deal, the co-founders of Panoptes, Dr. Franz Obermayr, a...

Expands Pipeline Beyond Ophthalmology with PP-001 , a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and Picomolar Potency to Avoid Off-Target Side Effects Acquisition Str...

Eyegate Pharmaceuticals (EYEG): Q3 GAAP EPS of -$0.44 misses by $0.02.Cash and cash equivalents of $2.93M10QPress Release For further details see: Eyegate Pharmaceuticals EPS misses by $0.02

WALTHAM, MA / ACCESSWIRE / November 9, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended September 30, 2020 and pr...